Enormous progress has been made in the last half-century in the management of diseases
closely integrated with excess body weight, such as hypertension, adult-onset diabetes and …

Background The glucagon-like peptide-1 (GLP-1) is a multifaceted hormone with broad
pharmacological potential. Among the numerous metabolic effects of GLP-1 are the glucose-…

Background The gastrointestinal peptide hormone ghrelin was discovered in 1999 as the
endogenous ligand of the growth hormone secretagogue receptor. Increasing evidence …

We present a consolidated view of the complexity and challenges of designing studies for
measurement of energy metabolism in mouse models, including a practical guide to the …

More than one-third of the worldwide population is overweight or obese and therefore at risk
of developing type 2 diabetes mellitus. In order to mitigate this pandemic, safer and more …

Background Obesity is a major health problem. Although heritability is substantial, genetic
mechanisms predisposing to obesity are not very well understood. We have performed a …

We report the discovery of a new monomeric peptide that reduces body weight and diabetic
complications in rodent models of obesity by acting as an agonist at three key metabolically-…

We report the discovery and translational therapeutic efficacy of a peptide with potent, balanced
co-agonism at both of the receptors for the incretin hormones glucagon-like peptide-1 (…

Meta-analyses of population-based genome-wide association studies (GWAS) in adults
have recently led to the detection of new genetic loci for obesity. Here we aimed to discover …

In the last two decades we have witnessed sizable progress in defining the role of gastrointestinal
signals in the control of glucose and energy homeostasis. Specifically, the molecular …